KIR3DL2 and cancer: Along the same line, to generate synergistic immunogenic effects against NK-dependent cancers including gastrointestinal stromal tumors, neuroblastomas, and kidney cancers, DCexo vaccines could be combined with NK-based therapies, such as anti-KIR Ab (anti-killer cell immunoglobulin-like receptor antibody) [97,98,99].